公开(公告)号：US20240350521A1

公开(公告)日：2024-10-24

申请号：US18641154

申请日：2024-04-19

Applicant: TAIPEI MEDICAL UNIVERSITY

Inventor： Yang-Ching CHEN

IPC: A61K31/704 ,  A61P5/24 ,  A61P15/00

CPC classification number: A61K31/704 ,  A61P5/24 ,  A61P15/00

Abstract: Provided is a method for preventing or treating precocious puberty in a subject in need thereof. The method includes administering to the subject an effective amount of glycyrrhizin or a salt or derivative thereof and an acceptable excipient thereof. Also provided is a composition for use in preventing or treating precocious puberty in a subject in need thereof.

公开(公告)号：US20240335381A1

公开(公告)日：2024-10-10

申请号：US18629522

申请日：2024-04-08

Applicant: Quicksilver Scientific, Inc.

Inventor： Christopher W. Shade ,  Steven Tieu ,  James R Huey

IPC: A61K9/107 ,  A61K9/00 ,  A61K31/57 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61P5/24

CPC classification number: A61K9/1075 ,  A61K9/0014 ,  A61K31/57 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61P5/24

Abstract: Thickened microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described thickened microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the thickened MOIW microemulsion are modified with alcohol and an alcohol-lipid phase thickener and can solubilize alcohol-soluble species, including nonderivatized hormones. Preferably, the modified oil phase droplets of the thickened MOIW microemulsion directly solubilize nonderivatized hormones. The polar continuous “water” phase of the thickened MOIW microemulsion is modified with a continuous phase thickener. The modified oil phase droplets disperse into the modified polar continuous phase of the thickened MOIW microemulsion.

公开(公告)号：US20240238237A1

公开(公告)日：2024-07-18

申请号：US18289409

申请日：2022-05-04

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

Inventor： Deborah J. Good

IPC: A61K31/201 ,  A61P1/14 ,  A61P3/04 ,  A61P5/24

CPC classification number: A61K31/201 ,  A61P1/14 ,  A61P3/04 ,  A61P5/24

Abstract: Described in certain example embodiments herein are methods of and compositions for treating a Snordl l6 deficiency disease or symptom thereof with conjugated linoleic acid (CLA) or a formulation thereof. In some embodiments, the Snordl l6 deficiency disease is Prader-Willi Syndrome. Described in certain example embodiments herein are methods of and compositions for treating Nhlh2 associated hypogonadism with CLA or a formulation thereof.

公开(公告)号：US12029719B2

公开(公告)日：2024-07-09

申请号：US17722918

申请日：2022-04-18

Applicant: Allen Morgan ,  Ariel Maxine Morgan ,  Karen Elizabeth Morgan

Inventor： Allen Morgan ,  Ariel Maxine Morgan ,  Karen Elizabeth Morgan

IPC: A61K31/352 ,  A61K36/185 ,  A61P5/24

CPC classification number: A61K31/352 ,  A61K36/185 ,  A61P5/24

Abstract: The present application discloses natural compositions as medicaments and wellness products comprising of one or more cannabinoids and little or no THC comprised with other natural ingredients used for alleviating premenstrual, menstrual, and menopausal symptoms such as hot flashes, night sweats, mood changes, nausea, and Premenstrual Syndrome (PMS). The invention also contemplates methods of use of said compositions.

公开(公告)号：US20240199754A1

公开(公告)日：2024-06-20

申请号：US18286895

申请日：2022-05-17

Applicant: VANCOUVER BIOTECH LTD.

Inventor： Chi-Yu Gregory Lee

IPC: C07K16/28 ,  A61K39/00 ,  A61P5/24

CPC classification number: C07K16/2869 ,  A61P5/24 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76

Abstract: GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fragment thereof can be used to control ovulation, terminate ectopic pregnancy, and/or treat reproductive disorders or conditions in mammalian subjects.

公开(公告)号：US20230125075A1

公开(公告)日：2023-04-27

申请号：US17790306

申请日：2021-01-04

Applicant: LG Household & Health Care Ltd.

Inventor： Sang Gwon Seo ,  Dong Jun Park ,  Ho Song Cho ,  Gil Nam Kim ,  Jae Hee Kim ,  Jun Hyeong Park ,  Mu Hyun Jin

IPC: A61K36/185 ,  A61P7/00 ,  A61P3/06 ,  A61P3/04 ,  A61P37/04 ,  A61P5/24 ,  A61P37/08 ,  A61P3/10 ,  A61P25/00 ,  A61P1/16 ,  A61K36/344 ,  A61K36/28 ,  A23L33/105 ,  A23C9/152 ,  A21D2/36 ,  A23L2/52 ,  A23L2/02

Abstract: The present invention relates to a composition including plant extracts. The composition according to the present invention has a blood circulation improvement effect by restoring nitric oxide (NO) reduced by oxLDL, has a cholesterol improvement effect by inhibiting cholesterol synthesis, has an anti-obesity effect by promoting breakdown of triglycerides, has an immune function improvement effect by increasing interferon gamma, has a female menopause improvement effect by activating estrogen signaling, has an anti-allergic effect by inhibiting IgE that causes allergies, has a blood glucose control effect by promoting intracellular glucose uptake, has a cognitive function improvement effect by inhibiting beta-secretase activity, has a liver health improvement effect by restoring liver cell viability decreased by alcohol (ethanol) treatment, and has an andropause improvement effect by activating androgen signaling. Due to these characteristics, the composition may be used as a pharmaceutical, food, or health functional food composition.

公开(公告)号：US20230000927A1

公开(公告)日：2023-01-05

申请号：US17941352

申请日：2022-09-09

Applicant: JangoBio, LLC

Inventor： Craig S. Atwood ,  Sivan Vadakkadath Meethal

IPC: A61K35/545 ,  A61K35/52 ,  A61K35/55 ,  A61P5/24 ,  A61P5/06 ,  C07K14/59 ,  A61K35/54 ,  A61K35/15 ,  A61K31/568 ,  A61K31/566 ,  A61K31/57

Abstract: Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.

公开(公告)号：US20220143037A1

公开(公告)日：2022-05-12

申请号：US17586228

申请日：2022-01-27

Applicant: Spruce Biosciences, Inc.

Inventor： Alexis HOWERTON ,  Hal GERBER ,  Michael HUANG

IPC: A61K31/5377 ,  A61P5/00 ,  A61K9/14 ,  A61K9/48 ,  A61P5/24 ,  A61K31/573 ,  C07D487/04 ,  A61P5/38

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

公开(公告)号：US20210338748A1

公开(公告)日：2021-11-04

申请号：US16324928

申请日：2017-08-11

Applicant: KOREA FOOD RESEARCH INSTITUTE

Inventor： Young-Do NAM ,  Yun-Tai KIM ,  Hee Soon SHIN ,  So-Young LEE ,  Jae-Goo KIM ,  Eun-Yeong LIM ,  Eun-Ji SONG

IPC: A61K35/747 ,  A23L33/135 ,  A61K8/99 ,  A61P5/24 ,  C12N1/20

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression. Therefore, it is expected that the composition comprising the Lactobacillus intestinalis according to the present invention can be usable for a use of preventing, alleviating, or treating menopause.

公开(公告)号：US10941152B2

公开(公告)日：2021-03-09

申请号：US16229119

申请日：2018-12-21

Applicant: TOCOPHERX, INC.

Inventor： Henry Yu ,  Changhe Qi ,  Paul Tempest ,  Selvaraj G. Nataraja ,  Stephen S. Palmer

IPC: C07D491/052 ,  A61P5/24 ,  A61P15/08 ,  A61K31/4162 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/541

Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).